2 Mar

How Demographics Are Shaping Generic Drug Growth

WRITTEN BY VanEck FEATURED IN Macroeconomic Analysis

Generics Continue to Lower Health Care Costs

Our population is aging and more people than ever are taking prescription drugs, contributing to the rising costs of health care. Consumers, insurance companies, and governments are all helping to fuel the growth of the generic drug industry by demanding lower-cost alternatives to brand name pharmaceuticals. In our view, generic pharmaceuticals can be seen as a timely and meaningful solution.

How Demographics Are Shaping Generic Drug Growth

Market Realist – Global demographics are undergoing a paradigm shift. The world is aging fast. Fertility rates keep falling while life expectancy keeps rising. According to the United Nations Population Fund, one in nine people in the world is currently older than 60. As living standards, healthcare, and welfare services continue to improve, the proportion of older people is likely to rise further. This demographic shift is likely to spur an increase in spending on healthcare and medicine. The generic drugs industry is likely to sustain robust growth in the coming years, and demographics are a key piece of the puzzle! In fact, demographics are shaping generic drug growth in a huge way.

The graph above shows the estimated over-65 population by country for 2010 and 2050. Emerging markets (VWO) like India (EPI)(SCIF) and Indonesia (IDX) have younger populations than the developed world (EFA).

How Demographics Are Shaping Generic Drug Growth

As you can see in the graph above, the world’s (ACWI) median age is likely to rise over the next three decades. With a rapidly aging population, the demand for healthcare (IYH) and medicine is likely to increase too.

How Demographics Are Shaping Generic Drug Growth

According to estimates from the Congressional Budget Office, entitlement programs will drive 60% of the increase in federal spending between 2014 and 2024. People’s need for prescription drugs tends to increase with age, and generic drugs’ cost effectiveness makes them crucial for reducing healthcare costs and federal budgets.

The demographic shift is a major tailwind for the pharmaceutical sector (PPH) in general and the generic drugs sector (GNRX) in particular. As the pressure to cater to an aging population increases, the need for cost-effective prescription drugs is likely to increase. In the next part of this series, we’ll explore why the generic drug market could mean savings for governments and their graying populations.

 

Latest articles

Yesterday, Apple (AAPL) launched a newly upgraded range of its iPad Air and iPad mini devices ahead of its March 25 special event.

19 Mar

Nike Gears Up to Deliver Its Q3 2019 Results

WRITTEN BY Sharon Bailey

Nike (NKE) is scheduled to report its earnings results for the third quarter of fiscal 2019 after the market closes on March 21.

On March 18, Chesapeake Energy’s (CHK) implied volatility was 51.9%, which is ~14.7% less than its 15-day average.

19 Mar

Sprint’s Revenue and Earnings Growth

WRITTEN BY Andrew Smith

Sprint (S) reported an adjusted EPS of $0.06 in the first nine months of fiscal 2018—compared to $0.08 during the same period in fiscal 2017.

19 Mar

Oil Bulls: US Oil Exports Tend to Fall More

WRITTEN BY Robert Scott

On March 18, Brent crude oil May futures settled ~$8.2 higher than the WTI crude oil May futures. On March 11, the spread was ~$9.5.

Out of the 34 analysts covering Broadcom (AVGO), 25 analysts rated the stock a “buy,” while nine analysts rated the stock a “hold."